FDA Finds Ranitidine Poses Little Risk, But Concerns Linger
Executive Summary
Ranitidine no more carcinogenic than grilled meat, says FDA drug center director Janet Woodcock. Agency finds NDMA levels in ranitidine drugs well below those claimed by Valisure, online pharmacy asking FDA to order drug off US market.
You may also be interested in...
Testing For Nitrosamine Impurities: Deadlines And Updates In EU, US, Canada, Malaysia, Australia
Drug companies deadlines are nearing to meet regulatory requirements relating to nitrosamine impurities found in their products as guidelines are being revised or re-published.
HBW Market Roundup: Expo West Postponed, FDA Needs International Cosmetics Meeting Input, More
New Hope Network postponed Natural Products Expo West trade show due to coronavirus; NPA supports Accurate Labels Act; American Health Packaging recalls OTC ranitidine; and FDA seeks input on topics for upcoming International Cooperation on Cosmetics Regulation meeting.
DeLauro Renews Push To Give FDA Mandatory Recall Authority For Drugs
"FDA’s failure to stop companies from selling ranitidine makes the United States government complicit in exposing infants and adults to the risk of cancer," says Rep. DeLauro in letter to FDA and HHS. She also re-introduced legislation proposing FDA have mandatory recall authority for drugs.